Oridonin inhibits breast cancer cell proliferation and migrationthrough suppressing COX-2 expression

Abstract

Oridonin, a biologically active substance isolated from the plant Rabdosia rubescens, is recently reported to have an
inhibitory effect on breast cancer. However, its mechanism is still unclear. According to previous findings, increased
COX-2 expression has been associated with a higher incidence of breast cancer. Therefore, this study aims to explore
whether oridonin inhibits cell proliferation and migration by suppressing the expression of COX-2 in human breast
cancer cells MDA-MB-231 in vitro and in vivo conditions. In this study, human breast cancer cells MDA-MB-231
will be treated with increasing concentrations and for various durations with oridonin to investigate whether oridonin
inhibits cell migration, decrease proliferation, and reduce tumors in mice through suppressing the expression of COX2. A positive control is a taxol. A negative control is medium. Cell migration will be tested by Transwell assay. The
proliferation will be detected by MTT assay. The western-blotting assay will be used for COX-2. In nude mice, the in
vivo anti-tumor efficacy of oridonin will be examined. The study’s result will provide insight into the effect of oridonin
on the proliferation and migration of human breast cancer cells MDA-MB-231. It will also provide reference for the
mechanism of how oridonin inhibits breast cancer and lay the foundation for future studies on the molecular basis of
oridonin’s pharmacological activity in the future.